Decision: Favourable

Study Title:

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Professor Ray McDermott

  • PI Institution:

    Tallaght University Hospital

  • Sponsor:

    Unicancer, Bayer

Scroll to Top